Title:
IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
Document Type and Number:
WIPO Patent Application WO/2019/112899
Kind Code:
A8
Abstract:
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
More Like This:
| WO/2019/180247 | METHOD FOR REPROGRAMMING SOMATIC CELLS |
| JP2016189783 | STEM CELL BANK FOR INDIVIDUAL MEDICAL CARE |
| WO/2022/187704 | ENGINEERED IMMUNE CELL THERAPIES |
Inventors:
VALAMEHR BAHRAM (US)
BJORDAHL RYAN (US)
LEE TOM (US)
GAIDAROVA SVETLANA (US)
BJORDAHL RYAN (US)
LEE TOM (US)
GAIDAROVA SVETLANA (US)
Application Number:
PCT/US2018/063362
Publication Date:
August 22, 2019
Filing Date:
November 30, 2018
Export Citation:
Assignee:
FATE THERAPEUTICS INC (US)
International Classes:
C12N5/074; A61K35/17; A61K35/545; A61K39/395; C07K14/735; C12N5/078; C12N5/0783
Attorney, Agent or Firm:
GAY, David, A. et al. (US)
Download PDF: